Table 4 Comparison between the Response and Non-Response Groups after rifaximin treatment at week 4
Clinical factors | Response group (n = 45) | Non-response group (n = 33) | P value |
|---|---|---|---|
Age (mean, years) | 34.82 ± 9.04 | 33.58 ± 8.84 | 0.544 |
Gender (M/F) | 31/14 | 21/12 | 0.627 |
LHBT (+/−) | 18/27 | 8/25 | 0.145 |
GI symptoms (mean) | 5.36 ± 3.27 | 13.79 ± 5.21 | < 0.001 |
Abdominal discomfort | 0.87 ± 0.89 | 2.45 ± 1.23 | < 0.001 |
Abdominal distension | 0.49 ± 0.70 | 1.67 ± 1.29 | < 0.001 |
Abdominal pain | 0.91 ± 0.93 | 2.27 ± 1.53 | < 0.001 |
Defecatory urgency | 1.09 ± 1.13 | 2.73 ± 1.26 | < 0.001 |
Diarrhea | 1.02 ± 0.97 | 2.42 ± 1.23 | < 0.001 |
Incomplete evacuation | 0.98 ± 1.03 | 2.33 ± 1.22 | < 0.001 |
Quality of life (mean) | 616.34 ± 84.06 | 545.34 ± 94.70 | 0.001 |
Physical Functioning | 97.33 ± 4.47 | 94.85 ± 5.93 | 0.048 |
Role-physical | 82.78 ± 24.90 | 67.42 ± 36.70 | 0.031 |
Bodily pain | 77.34 ± 13.70 | 62.36 ± 19.88 | < 0.001 |
General Health | 59.22 ± 16.52 | 45.64 ± 16.70 | 0.001 |
Vitality | 67.33 ± 15.06 | 61.67 ± 14.23 | 0.094 |
Social Functioning | 85.63 ± 10.52 | 76.67 ± 19.98 | 0.012 |
Role-Emotional | 76.30 ± 32.28 | 72.73 ± 30.57 | 0.621 |
Mental Health | 70.40 ± 16.30 | 64.00 ± 18.08 | 0.112 |